INOZYME PHARMA INC. - COMMON STOCK

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

27 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at Upcoming Investor Conferences

11 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

05 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

24 Oct 2024 13:15:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

17 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

07 Oct 2024 08:30:17 By Nasdaq GlobeNewswire

Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

29 Aug 2024 08:30:23 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

06 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

25 Jul 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

02 Jul 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

21 Jun 2024 13:00:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

30 May 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

23 May 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

08 May 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

07 May 2024 08:30:44 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 08:30:02 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

08 Apr 2024 06:30:35 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 18:00:00 By Nasdaq GlobeNewswire